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ABSTRACT 
Exosomes are small membrane vesicles that are secreted by cells as means of 
intercellular communication. They are typically between 50 and 100 nm in diameter 
and originate from the endosomal compartment of cells. Exosomes have been 
considered a potential novel cell-free therapeutic agent since exosomes are capable of 
antigen presentation. Indeed, exosomes from dendritic cells can activate the innate and 
adaptive immune systems, can establish protective immunity in various models of 
infectious diseases and can eradicate established tumors in mice. However, using 
exosomes in the clinic has proven difficult and need optimization to induce a sufficient 
immune response. Research now focuses on a) using exosomes as biomarkers and 
diagnostic tools for neoplastic diseases and b) understanding the exosomal immune 
response and finding ways to increase the immunogenicity of exosomes.  
This thesis aimed at 1) clarifying mechanisms important for the exosomal immune 
response, 2) identifying new ways to increase immunogenicity of exosomes, and 3) 
studying the relevance of exosomes in a human inflammatory disease, atopic eczema 
(AE). We report that exosomes from murine bone marrow-derived dendritic cells (DCs) 
can induce CD4+ T cell responses in a B cell-dependent manner. By comparing 
exosomes loaded with the whole ovalbumin (OVA) protein to exosomes loaded with 
the dominant CD4+ T cell epitope we found that only whole OVA-loaded exosomes 
could induce memory T and B cell responses in vivo. Interestingly, T cell activation 
was absent in Bruton kinase knockout (btk-/-) mice lacking a functional B cell 
compartment. Further, we found that bone marrow DC-derived exosomes express 
CD1d and can activate natural killer T cells (NKT cells) in vitro and in vivo. Activation 
of NKT cells subsequently amplified innate NK cell and γδ T cell responses as well as 
OVA-specific CD4+ T cell, CD8+ T cell and B cell responses. Our data suggest that 
exosome-induced antibody production is linked to subsequent activation of T follicular 
helper cells, germinal center B cells and plasma cells. In a third study, using exosomes 
from human monocyte-derived DCs, macrophages and plasma, we discovered a novel 
inflammatory property of exosomes. We found that exosomes contain enzymes of the 
leukotriene pathway and that they could produce high amounts of leukotriene B4 and 
C4 when incubated with the intermediate leukotriene A4. Exosomes could also induce 
granulocyte migration, which increased when incubated with the substrate AA. Finally, 
we found that the commensal yeast Malassezia sympodialis secreted nanovesicles that 
carry M. sympodialis allergens and induced significantly higher IL-4 responses in 
peripheral blood mononuclear cells (PBMC) of AE patients sensitized to the yeast than 
in PBMC of healthy controls (HC). Nanovesicles induced TNF-α production in PBMC 
of both groups. Further, we find that exosomes from monocyte-derived DCs, co-
cultured with M. sympodialis induce significantly higher IL-4 and TNF-α responses 
than exosomes from unstimulated DCs in PBMC of both AE patients and HC. This 
suggests a role for nanovesicles in the allergic immune response.  
In summary, we have identified three new pathways, which might be exploited to 
induce more potent immune responses to exosomes. Including B cell epitopes and 
CD1d ligands as well as exploiting the chemoattractive capacity of exosomes when 
designing future exosomal vaccines might increase the efficacy in a clinical setting. The 
finding that immunogenic nanovesicles are produced by M. sympodialis highlights 
novel host microbe interactions in AE and emphasizes the immunostimulatory potential 
of exosomes also in humans. 
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